Get the Stockscreener App
19.14
4.08%
0.75
After Hours:
18.87
-0.27
-1.41%
10 X Genomics Inc stock is traded at $19.14, with a volume of 3.20M.
It is up +4.08% in the last 24 hours and up +1.32% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$18.39
Open:
$18.54
24h Volume:
3.20M
Relative Volume:
1.28
Market Cap:
$2.45B
Revenue:
$642.82M
Net Income/Loss:
$-43.54M
P/E Ratio:
-54.75
EPS:
-0.3496
Net Cash Flow:
$130.12M
1W Performance:
+14.68%
1M Performance:
+1.32%
6M Performance:
+53.24%
1Y Performance:
+84.22%
1-Day Range:
$18.30
$19.48
1-Week Range:
$16.69
$19.48
52-Week Range:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, MMED
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
19.14 | 2.35B | 642.82M | -43.54M | 130.12M | -0.3496 |
VEEV
Veeva Systems Inc
|
185.23 | 30.26B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
49.14 | 8.40B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
42.10 | 7.92B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
81.64 | 6.84B | 1.31B | 215.20M | 408.32M | 2.4627 |
MMED
Minimed Group Inc
|
17.10 | 4.65B | 0 | 0 | 0 | 0.00 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
These Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley Fool
10x Genomics Stock Analysis: Recent Gains vs. Long-Term Growth Challenges | 2026News and Statistics - IndexBox
10X Genomics Hits Day High with 8.39% Surge Amid Market Volatility - Markets Mojo
ARK Investment Increases Stake in 10x Genomics (TXG) with Major Purchase - GuruFocus
Cathie Wood’s ARK adds 10x Genomics stock, trims Arcturus - Investing.com
10X Genomics Stock Hits Day Low of $15.90 Amid Price Pressure - Markets Mojo
10x Genomics Inc Class A Trade Ideas — LSX:A2PPQJ - TradingView
10x Genomics Inc (TXG) Trading Down 10.96% on Mar 16 - GuruFocus
10x Genomics Shares Drop 10.9% Amid Market Volatility - National Today
10x Genomics (NASDAQ:TXG) Shares Down 10.9%Here's Why - MarketBeat
10x Genomics (TXG) Shares Drop Nearly 14% - GuruFocus
TXG SEC Filings10X Genomics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Cathie Wood’s ARK trims 10X Genomics stock, adds DraftKings - Investing.com Nigeria
Cathie Wood’s ARK stock trades highlight CRISPR buys, 10x Genomics sells - Investing.com
Cathie Wood’s ARK stock trades highlight CRISPR buys, 10x Genomics sells By Investing.com - Investing.com South Africa
10X Genomics Experiences Evaluation Revision Amid Mixed Market Signals and Performance Metrics - Markets Mojo
10X Genomics Stock Hits Day Low of $18.80 Amid Price Pressure - Markets Mojo
Dynamic Technology Lab Private Ltd Has $1.13 Million Stock Holdings in 10x Genomics $TXG - MarketBeat
Level Four Advisory Services LLC Acquires New Position in 10x Genomics $TXG - MarketBeat
Smart Money: Can 10x Genomics Inc grow without dilutionWeekly Trend Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Risk Report: Can 10x Genomics Inc grow without dilutionJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
10x Genomics $TXG Shares Bought by JPMorgan Chase & Co. - MarketBeat
Citigroup Inc. Increases Holdings in 10x Genomics $TXG - MarketBeat
Citigroup Boosts Stake in 10x Genomics - National Today
ARK Investment Cuts Stake in 10x Genomics - National Today
10x genomics CEO Saxonov sells $367,096 in shares - Investing.com UK
10x Genomics $TXG Shares Sold by ARK Investment Management LLC - MarketBeat
Amova Asset Management Americas Inc. Has $62.86 Million Stock Holdings in 10x Genomics $TXG - MarketBeat
10x Genomics (TXG) CEO sells shares and makes stock gift - Stock Titan
TXG Technical Analysis & Stock Price Forecast - Intellectia AI
10x Genomics $TXG Position Lifted by Vanguard Group Inc. - MarketBeat
10X Genomics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Breaking Down 10x Genomics: 11 Analysts Share Their Views - Sahm
Commit To Buy 10x Genomics At $15, Earn 20.6% Annualized Using Options - Nasdaq
TXG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Ascendis Pharma (ASND) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Stifel Nicolaus Boosts 10x Genomics Price Target to $25 - National Today
Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan
88,816 RSUs awarded to 10x Genomics (TXG) director Hindson - Stock Titan
10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award - Stock Titan
TXG affiliate files Form 144: proposed Class A Common sale (NASDAQ: TXG) - Stock Titan
10X Genomics Hits Day High with Strong 12.56% Intraday Surge - Markets Mojo
10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Is It Time To Reassess 10x Genomics (TXG) After Its 1 Year Share Price Surge - Yahoo Finance
10x Genomics (NASDAQ:TXG) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is 10x Genomics Inc.’s ROIC above industry averageTrade Performance Summary & AI Driven Price Forecasts - mfd.ru
Insider Sell: Sarah Teichmann Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan - Stock Titan
Is It Time To Reassess 10x Genomics (TXG) After Its 105% One Year Surge - simplywall.st
10x Genomics (TXG) Price Target Increased by 10.28% to 20.33 - Nasdaq
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):